Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030

Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030

“DelveInsight Business Research LLP”
DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) – Market Insights, Epidemiology and Market Forecast – 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

DelveInsight has introduced a new report on “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030” to its portfolio.

The growth of NSCLC Market is expected to increase due to increasing incident cases of NSCLC, continuous uptake of approved therapies mainly immune checkpoint inhibitors, increasing use of biomarker testing, probable entry of potential premium price emerging therapies and increasing awareness of mutations, among others.

Key Highlights from the report are:

  • As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.
  • There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
  • The market size of NSCLC in the 7MM is expected to increase during study period. According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by JapanGermany, and the UK.
  • One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.

Request for free sample pages to get a detailed view on Non-Small Cell Lung Cancer Market Forecast 

NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.

The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.

NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. 

The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.

Drugs covered in the report are:-

There are several key players robustly involved in developing potential products such as

  • Nazartinib (EGF816)
  • Capmatinib (INC280)
  • Tepmetko (tepotinib)
  • Merestinib
  • JNJ-61186372 (JNJ-6372)
  • Vemurafenib Plus Cobimetinib
  • X-396 (Ensartinib)
  • Tedopi (OSE2101)
  • Selpercatinib (LY3527723/ LOXO-292)
  • SAR408701
  • Braftovi (encorafinib) + Mektovi (binimetinib)
  • PADCEV (enfortumab vedotin/ASG-22ME)
  • Pralsetinib (BLU-667)
  • TAK-788: Canakinumab (ACZ885)
  • Avelumab (Bavencio)
  • Veliparib (ABT-888): Sitravatinib (MGCD516)
  • Tesevatinib
  • Romiplostim: Cabozantinib
  • Sym015
  • AMG 510
  • INCMGA00012 (MGA012)
  • Libtayo (Cemiplimab)
  • Bavituximab
  • M7824 (Bintrafusp alfa)
  • And many others

Key Players covered in the report are:-

  • Novartis Pharmaceuticals
  • Merck KGaA
  • Eli Lilly and Company
  • Janssen Research & Development
  • Hoffmann-La Roche
  • Xcovery
  • BeyondSpring Pharmaceuticals
  • OSE Immunotherapeutics
  • Sanofi
  • Pfizer
  • Astellas Pharma
  • Seattle Genetics
  • Blueprint Medicines Corporation
  • Takeda
  • AbbVie
  • Kadmon Corporation
  • Amgen
  • Symphogen
  • Regeneron Pharmaceuticals
  • Peregrine Pharmaceuticals
  • Avid Bioservices
  • GlaxoSmithKline

And many others

Table of contents:

1.   Key Insights

2.   Executive Summary of NSCLC

3.   SWOT Analysis of NSCLC

4.   NSCLC: Market Overview at a Glance

4.1.  Total Market Share (%) Distribution of NSCLC in 2017: By Country

4.2.  Total Market Share (%) Distribution of NSCLC in 2030: By Country

4.3.  Total Market Share (%) Distribution of NSCLC in 2017: By Mutations/ biomarkers

4.4.  Total Market Share (%) Distribution of NSCLC in 2030: By Mutations/ biomarkers

4.5.  NSCLC Revenue Summary by Mutations/ biomarkers

5.   Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview

5.1.  Introduction

5.1.1. Cellular Classification of NSCLC

5.1.2. Signs and Symptoms of NSCLC

5.1.3. Risk Factors of Lung Cancer

5.1.4. Causes of NSCLC

5.1.5. Disease Biology: NSCLC

6.   Diagnosis of NSCLC

6.1.  Diagnostic Algorithm for NSCLC

6.2.  Stages of NSCLC

6.3.  Staging System

7.   Epidemiology and Patient Population

7.1.  Epidemiology Key Findings

7.2.  Assumptions and Rationale: 7MM

7.3.  Epidemiology Scenario: 7MM

7.3.1. Total Incident cases of NSCLC patients in the 7MM

7.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM

7.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM

7.4. The United States Epidemiology

7.4.1. Total Incident cases of NSCLC patients in the United States

7.4.2. Total Incident cases of NSCLC patients by Histology in the United States

7.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States

7.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United States

8.   EU-5 Epidemiology

8.1.  Germany

8.1.1. Total Incident cases of NSCLC patients in Germany

8.1.2. Total Incident cases of NSCLC patients by Histology in Germany

8.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany

8.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Germany

8.2.  France

8.2.1. Total Incident cases of NSCLC patients in France

8.2.2. Total Incident cases of NSCLC patients by Histology in France

8.2.3. Total Diagnosed cases of NSCLC patients by Stages in France

8.2.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in France

8.3.  Italy

8.3.1. Total Incident cases of NSCLC patients in Italy

8.3.2. Total Incident cases of NSCLC patients by Histology in Italy

8.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy

8.3.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Italy

8.4.  Spain

8.4.1. Total Incident cases of NSCLC patients in Spain

8.4.2. Total Incident cases of NSCLC patients by Histology in Spain

8.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain

8.4.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Spain

8.5.  The United Kingdom

8.5.1. Total Incident cases of NSCLC patients in the United Kingdom

8.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom

8.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom

8.5.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in the United Kingdom

9.   Japan Epidemiology

9.1.  Japan

9.1.1. Total Incident cases of NSCLC patients in Japan

9.1.2. Total Incident cases of NSCLC patients by Histology in Japan

9.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan

9.1.4. Total NSCLC cases of patients by Genetic mutation/Biomarkers in Japan

10. Current Treatment Practices: NSCLC

10.1.  Advanced/Metastatic NSCLC Treatment Algorithm

10.2.  Chemotherapy

10.3.  Targeted Therapy

10.4.  Immunotherapy

10.5.  Surgery

10.6.  Radiation Therapy

10.7.  Stage-wise Treatment Options of NSCLC

11. Guideline of NSCLC

11.1.  The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2020

11.2.  The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

11.3.  The Spanish Society of Medical Oncology (SEOM) Clinical Guidelines: 2018

11.4.  The Japanese Lung Cancer Society Guideline for NSCLC, Stage IV: 2018

12. Unmet Needs of NSCLC

13. Key Endpoints in NSCLC Clinical Trials

14. Marketed Therapies

14.1. Key Cross

14.2. Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)

14.2.1. Product Description

14.2.2. Regulatory Milestones

14.2.3. Other Developmental Activities

14.2.4. Pivotal Clinical Trials

14.2.5. Ongoing Current Pipeline Activity

14.3. Imfinzi (Durvalumab): AstraZeneca

14.3.1. Product Description

14.3.2. Regulatory Milestones

14.3.3. Other Developmental Activities

14.3.4. Pivotal Clinical Trials

14.3.5. Ongoing Current Pipeline Activity

14.3.6. Safety and Efficacy of Ongoing Clinical Trials

14.4. Opdivo (Nivolumab): Bristol-Myers Squibb

14.4.1. Product Description

14.4.2. Regulatory Milestones

14.4.3. Other Developmental Activities

14.4.4. Pivotal Clinical Trials

14.4.5. Ongoing Current Pipeline Activity

14.5. Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche

14.5.1. Product Description

14.5.2. Regulatory Milestones

14.5.3. Other Developmental Activities

14.5.4. Pivotal Clinical Trials

14.5.5. Ongoing Current Pipeline Activity

14.6. Keytruda (Pembrolizumab): Merck

14.6.1. Product Description

14.6.2. Regulatory Milestones

14.6.3. Other Developmental Activities

14.6.4. Pivotal Clinical Trials

14.6.5. Ongoing Current Pipeline Activity

14.7. Tafinlar(Dabrafenib)in Combination with Mekinist(Trametinib): Novartis

14.7.1. Product Description

14.7.2. Regulatory Milestones

14.7.3. Other Developmental Activities

14.7.4. Pivotal Clinical Trials

14.8. Tagrisso(Osimertinib): AstraZeneca

14.8.1. Product Description

14.8.2. Regulatory Milestones

14.8.3. Other Developmental Activities

14.8.4. Pivotal Clinical Trials

14.8.5. Ongoing Current Pipeline Activity

14.9. Lorbrena/Lorviqua (Lorlatinib): Pfizer

14.9.1. Product Description

14.9.2. Regulatory Milestones

14.9.3. Other Developmental Activities

14.9.4. Pivotal Clinical Trials

14.9.5. Ongoing Current Pipeline Activity

14.10. Vizimpro(Dacomitinib): Pfizer

14.10.1. Product Description

14.10.2. Regulatory Milestones

14.10.3. Other Developmental Activities

14.10.4. Pivotal Clinical Trials

14.10.5. Ongoing Current Pipeline Activity

14.11. Alunbrig (Brigatinib): Takeda Pharmaceuticals

14.11.1. Product Description

14.11.2. Regulatory Milestones

14.11.3. Pivotal Clinical Trials

14.11.4. Ongoing Current Pipeline Activity

14.11.5. Safety and Efficacy of Ongoing Clinical Trials

14.12. Alecensa (Alectinib): Hoffmann-La Roche

14.12.1. Product Description

14.12.2. Regulatory Milestones

14.12.3. Other Developmental Activities

14.12.4. Pivotal Clinical Trials

14.12.5. Ongoing Current Pipeline Activity

14.13. Vitrakvi (Larotrectinib): Bayer Healthcare

14.13.1. Product Description

14.13.2. Regulatory Milestones

14.13.3. Other Developmental Activities

14.13.4. Pivotal Clinical Trials

14.13.5. Safety and Efficacy

14.14. Portrazza (Necitumumab): Eli Lilly

14.14.1. Product Description

14.14.2. Regulatory Milestones

14.14.3. Other Developmental Activities

14.14.4.  Pivotal Clinical Trials

14.14.5.  Ongoing Current Pipeline Activity

15. Emerging Therapies

15.1. Nazartinib (EGF816): Novartis Pharmaceuticals

15.1.1. Product Description

15.1.2. Clinical Development

15.1.3. Safety and Efficacy

15.2. Capmatinib (INC280): Novartis Pharmaceuticals

15.2.1. Product Description

15.2.2. Other Development Activities

15.2.3. Clinical Development

15.2.4. Safety and Efficacy

15.3. Tepmetko (tepotinib): Merck KGaA

15.3.1. Product Description

15.3.2. Other Development Activities

15.3.3. Clinical Development

15.3.4. Safety and Efficacy

15.4. Merestinib: Eli Lilly and Company

15.4.1. Product Description

15.4.2. Clinical Development

15.4.3. Telisotuzumab Vedotin: AbbVie

15.4.4. Product Description

15.4.5. Clinical Development

15.4.6. Safety and Efficacy

15.5. JNJ-61186372 (JNJ-6372): Janssen Research & Development

15.5.1. Product Description

15.5.2. Other Development Activity

15.5.3. Clinical Development

15.5.4. Safety and Efficacy

15.6. Lazertinib: Yuhan Corporation/ Janssen Research & Development

15.6.1. Product Description

15.6.2. Clinical Development

15.6.3. Safety and Efficacy

15.7. Vemurafenib Plus Cobimetinib: Hoffmann-La Roche

15.7.1. Product Description

15.7.2. Clinical Development

15.7.3. Safety and Efficacy

15.8. X-396 (Ensartinib): Xcovery

15.8.1. Product Description

15.8.2. Clinical Development

15.8.3. Safety and Efficacy

15.9. Plinabulin: BeyondSpring Pharmaceuticals

15.9.1. Product Description

15.9.2. Clinical Development

15.9.3. Safety and Efficacy

15.10. (OSE2101): OSE Immunotherapeutics

15.10.1. Description

15.10.2. Development

15.10.3  Safety and Efficacy

15.11. Selpercatinib (LY3527723/ LOXO-292): Eli Lilly and Company

15.11.1. Product Description

15.11.2. Clinical Development

15.11.3. Safety and Efficacy

15.12. SAR408701: Sanofi

15.12.1. Product Description

15.12.2. Clinical Development

15.13. Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer

15.13.1. Product Description

15.13.2. Clinical Development

15.14. PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics

15.14.1. Product Description

15.14.2. Clinical Development

15.15. Pralsetinib (BLU-667): Blueprint Medicines Corporation

15.15.1. Product Description

15.15.2. Clinical Development

15.15.3. Safety and Efficacy

15.16.TAK-788: Takeda

15.16.1. Product Description

15.16.2. Clinical Development

15.16.3. Safety and Efficacy

15.17. Canakinumab (ACZ885): Novartis Pharmaceuticals

15.17.1. Product Description

15.17.2. Clinical Development

15.18. Avelumab (Bavencio): Merck KGaA and Pfizer

15.18.1. Product Description

15.18.2. Clinical Development

15.18.3. Safety and Efficacy

15.19. Veliparib (ABT-888): AbbVie

15.19.1.Product Description

15.19.2.Clinical Development

15.19.3. Safety and Efficacy

15.20. Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene

15.20.1. Product Description

15.20.2. Other Developmental Activities

15.20.3. Clinical Development

15.20.4. Safety and Efficacy

15.21. Tesevatinib: Kadmon Corporation

15.21.1. Product Description

15.21.2. Clinical Development

15.21.3. Safety and Efficacy

15.22. Romiplostim: Amgen

15.22.1. Product Description

15.22.2. Clinical Development

15.23. Cabozantinib: Exelixis/Ipsen/Takeda

15.23.1. Product Description

15.23.2. Other Development Activities

15.23.3. Clinical Development

15.23.4. Safety and Efficacy

15.24. Sym015: Symphogen

15.24.1. Product Description

15.24.2. Clinical Development

15.24.3. Safety and Efficacy

15.25. AMG 510: Amgen

15.25.1. Product Description

15.25.2. Clinical Development

15.25.3. Safety and Efficacy

15.26. INCMGA00012 (MGA012): Incyte Corporation/ Zai Lab Limited

15.26.1. Product Description

15.26.2. Clinical Development

15.27. Libtayo (Cemiplimab): Regeneron Pharmaceuticals

15.27.1. Product Description

15.27.2. Clinical Development

15.27.3. Safety and Efficacy

15.28. Bavituximab: Peregrine Pharmaceuticals/ Avid Bioservices, Inc

15.28.1. Product Description

15.28.2. Clinical Development

15.28.3. Safety and Efficacy

15.29. M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA

15.29.1. Product Description

15.29.2. Clinical Development

15.29.3. Safety and Efficacy

16. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis

16.1. Key Findings

16.2. Market Outlook: 7MM

17. PD-L1—Market Size

17.1. Total Market Size of PD-L1 NSCLC in the 7MM

17.2. Market Size of PD-L1 NSCLC by Therapeutic Class in the 7MM

17.3. United States Market Size

17.3.1. Total Market size of PD-L1 NSCLC in the United States

17.4. EU-5 Market Size

17.4.1. Germany Market Size

17.4.2. France Market Size

17.4.3. Italy Market Size

17.4.4. Spain Market Size

17.4.5. United Kingdom Market Size

17.5. Japan Market Size

17.5.1. Total Market size of PD-L1 NSCLC in Japan

18. BRAF Mutation—Market Size

18.1. Total Market Size of BRAF NSCLC in the 7MM

18.2. Market Size of BRAF-NSCLC by Therapeutic Class in the 7MM

18.3. United States Market Size

18.3.1. Total Market size of BRAF NSCLC in the United States

18.4. EU-5 Market Size

18.4.1. Germany Market Size

18.4.2. France Market Size

18.4.3. Italy Market Size

18.4.4. Spain Market Size

18.4.5. United Kingdom Market Size

18.5. Japan Market Size

18.5.1. Total Market size of BRAF NSCLC in Japan

19. c-MET Mutation—Market Size

19.1. Total Market Size of c-MET NSCLC in the 7MM

19.2. Market Size of c-MET NSCLC by Therapeutic Class in the 7MM

19.3. United States Market Size

19.3.1. Total Market size of c-MET NSCLC in the United States

19.4. EU-5 Market Size

19.4.1. Germany Market Size

19.4.2. France Market Size

19.4.3. Italy Market Size

19.4.4. Spain Market Size

19.4.5. United Kingdom Market Size

19.5. Japan Market Size

19.5.1. Total Market size of c-MET NSCLC in Japan

20. EGFR Mutation—Market Size

20.1. Total Market Size of EGFR-positive NSCLC in the 7MM

20.2. Market Size of EGFR-positive NSCLC by Therapeutic Class in the 7MM

20.3. United States Market Size

20.3.1. Total Market size of EGFR NSCLC in the United States

20.4. EU-5 Market Size

20.4.1. Germany Market Size

20.4.2. France Market Size

20.4.3. Italy Market Size

20.4.4. Spain Market Size

20.4.5. United Kingdom Market Size

20.5. Japan Market Size

20.5.1. Total Market size of NSCLC in Japan

21. ALK-Mutation—Market Size

21.1. Total Market Size of ALK NSCLC in the 7MM

21.2. Market Size of ALK NSCLC by Therapeutic Class in the 7MM

21.3. United States Market Size

21.3.1. Total Market size of ALK NSCLC in the United States

21.4. EU-5 Market Size

21.4.1. Germany Market Size

21.4.2. France Market Size

21.4.3. Italy Market Size

21.4.4. Spain Market Size

21.4.5. United Kingdom Market Size

21.5. Japan Market Size

21.5.1. Total Market size of NSCLC in Japan

22. Market Access and Reimbursement of NSCLC Therapies

23. Market Drivers of NSCLC

24. Market Barriers of NSCLC

25. Appendix

25.1. Bibliography

25.2. Report Methodology

26. DelveInsight Capabilities

27. Disclaimer

28. About DelveInsight

Related Reports:

About DelveInsight 

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/